Cat. No.: DIA-0230674
Product Information | |
---|---|
CAS No. | 52659-56-0 |
Formula | C20H34O4 |
Molecular Weight | 338.48 |
SMILES | CC1(CO)CC(O)CC2(C)C3CCC(C)(C=C3CCC12)C(O)CO |
Product Description | Kirenol possesses anti-oxidant, anti-inflammatory, anti-allergic, and anti-arthritic activities. Kirenol is effective against gram-positive bacteria. Kirenol may be a potential immunosuppressant for the treatment for rheumatoid arthritis. Kirenol has significant potential for its discovery as a new lead compound for management of topical pain and inflammation. Kirenol is capable of inhibiting the differentiation and lipogenesis of 3T3-L1 adipocytes through the activation of the Wnt/β-catenin signaling pathway, suggesting its potential as natural anti-obesity agent. Kirenol can upregulate nuclear Annexin-1 which interacts with NF-κB to attenuate synovial inflammation of collagen-induced arthritis in rats. Kirenol can attenuate experimental autoimmune encephalomyelitis by inhibiting differentiation of Th1 and th17 cells and inducing apoptosis of effector T cells. 8. Kirenol possesses antitumor action on human chronic myeloid leukemia K562 cells in vitro, it may have therapeutic potential for the treatment of cancer that deserves further investigation. 9. Kirenol is a potential candidate target for treating or preventing osteoporosis, it is capable of promoting osteoblast differentiation in MC3T3-E1 cells through activation of the BMP and Wnt/β-catenin signaling pathways. |
Format & Storage | |
---|---|
Purity | > 99% |
Shipping | Shipped on dry ice. |
Storage | Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month |
Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.